Remove 2016 Remove Clinical Development Remove Clinical Pharmacology Remove Pharmacy
article thumbnail

Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine

Agency IQ

In August 2016, the CHPA provided a lengthy comment asserting, essentially, that the petitioners had already sought relief in its earlier petition and that the Nonprescription Drugs Advisory Committee (NDAC) had addressed the concerns raised again in this latest petition. The two sides saw nearly every finding in a different light.

Science 40
article thumbnail

Analysis Life Sciences Thank You The FDA and oncology: 2023 year in review

Agency IQ

Oncology at FDA in 2023: A quick glance at the numbers First created under the 21st Century Cures Act of 2016 and launched in 2017, FDA’s Oncology Center of Excellence (OCE ) “unites experts across the FDA to conduct expedited review of medical products for oncologic and hematologic malignancies.”

FDA 40